Rockwell Appoints Gupta as Chief Scientific Officer

WIXOM, Mich.—Rockwell Medical Technologies has appointed Ajay Gupta, MD, to be its chief scientific officer.

Gupta will continue to play a role in the development and commercialization of the Rockwell’s lead drug Soluble Ferric Pyrophosphate (SFP), indicated for the treatment of iron deficiency anemia in hemodialysis patients.

As chief scientific officer, Gupta will be responsible for the identification and development of new drug opportunities in the areas of women's health, oncology and parenteral nutrition based on the SFP platform, as well as new drugs for other targeted renal therapies and indications.

"We are thrilled to have Ajay join Rockwell and strengthen our scientific team,” Robert L. Chioini, chairman, CEO and president of Rockwell said. “His decades of work in both the academic and medical fields, coupled with his extensive knowledge in the anemia and iron space, will be an invaluable asset to us as we continue to drive SFP through clinical development and capitalize on other potential therapeutic opportunities, positioning Rockwell as a dynamic bio-pharma company."

Prior to joining Rockwell, Gupta spent the last seven years as an associate professor of medicine at UCLA and CharlesDrewUniversitySchools of Medicine, where he has had an active nephrology practice.

Gupta is the inventor of dialysate iron therapy using Soluble Ferric Pyrophosphate (SFP) and is also the inventor of intravenous (IV) iron therapy using slow continuous infusion of SFP, including as an adjunct to parenteral nutritional admixtures. He has filed a number of patents in the areas of drugs, medical devices and diagnostic tests.